Immuron (IMRN) Income from Continuing Operations (2016 - 2024)
Immuron's (IMRN) quarterly Income from Continuing Operations came in at 37936939932.02 in Q4 2024, up 1829989.51% year-on-year from N/an in Q1 2024, and up 1829989.51% quarter-over-quarter from 2073182.0 in Q4 2023.
Immuron (IMRN) Income from Continuing Operations (2016 - 2024) Analysis & Trends
Immuron's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 37936939932.02 for Q4 2024.
- On a quarterly basis, Income from Continuing Operations rose 1829989.51% year-over-year to 37936939932.02 in Q4 2024; TTM through Dec 2024 was 37933275558.96, a 1031558.91% increase from a year earlier, with the FY2025 full-year figure at 3380634.04, down 227575.8% from the prior year.
- Income from Continuing Operations advanced to 37936939932.02 in Q4 2024 per IMRN's latest filing, from 2073182.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 37936939932.02 in Q4 2024 and bottomed at 2073182.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 204929.12 (2022), against an average of 6322200818.51.
- Across the five-year window, Income from Continuing Operations tumbled 2558.11% in 2022 and jumped 1829989.51% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 57387.72 in 2020, then soared by 76.89% to 13260.17 in 2021, then tumbled by 2558.11% to 352470.52 in 2022, then slumped by 488.19% to 2073182.0 in 2023, then soared by 1829989.51% to 37936939932.02 in 2024.
- Per Business Quant, the three latest IMRN Income from Continuing Operations figures stand at 37936939932.02 (Q4 2024), 2073182.0 (Q4 2023), and 1238720.54 (Q2 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Immuron | 255.19 Mn | 243.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 37.94 Bn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -352,470.52 |
| Dec 31, 2021 | -13,260.17 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | -1.45 Mn |
| Dec 31, 2016 | -2.60 Mn |
| Jun 30, 2016 | -3.28 Mn |